Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32588067.
- Also identified by DOI 10.1007/s00134-020-06154-8 and PMC identifier 7315695.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.
Medical subject headings
- Anesthetics, Inhalation
- Betacoronavirus
- Coronavirus Infections
- Hypnotics and Sedatives
- Pneumonia, Viral
- Respiratory Distress Syndrome